Foghorn Therapeutics Inc. Common Stock
FHTX Real Time Price USDRecent trades of FHTX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by FHTX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Compounds and uses thereof Nov. 12, 2024
-
Patent Title: Compounds and uses thereof Dec. 26, 2023
-
Patent Title: Brd9 degraders and uses thereof Oct. 17, 2023
-
Patent Title: Methods and compounds for treating disorders Oct. 03, 2023
-
Patent Title: Citrate salt, pharmaceutical compositions, and methods of making and using the same Sep. 26, 2023
-
Patent Title: Compounds and uses thereof Jan. 24, 2023
-
Patent Title: Compounds and uses thereof Nov. 15, 2022
-
Patent Title: Compounds and uses thereof Nov. 01, 2022
-
Patent Title: Compounds and uses thereof Aug. 16, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of FHTX in WallStreetBets Daily Discussion
Recent insights relating to FHTX
Recent picks made for FHTX stock on CNBC
ETFs with the largest estimated holdings in FHTX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view FHTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.